Vitamin B12 Dosage: Amounts Used in Human Studies

A bottle may say 5,000 mcg. A clinic may say 1,000 mcg by injection. A government table may say 2.4 mcg. All three numbers are real, and none contradicts the others. Understanding vitamin B12 dosage means knowing which question each number answers: how much you need to stay healthy, how much was given in a trial, or how much a clinician used to treat deficiency. This guide summarizes the amounts used in human research, explains why the range is so wide, and shows how to read the numbers without mistaking them for personal advice.

1. Quick Answer and Medical Disclaimer

The short version:

• The recommended dietary intake for most adults is small: 2.4 micrograms (mcg) per day in the United States, with 2.6 mcg in pregnancy and 2.8 mcg during lactation (NIH Office of Dietary Supplements; National Academies, 1998).
• Supplements and treatments use far larger amounts, because only a small fraction of a large oral dose is absorbed.
• In human studies of deficiency, oral doses have commonly been about 1,000 to 2,000 mcg daily, and intramuscular regimens have commonly used 1,000 mcg per injection on a loading and maintenance schedule.
• Some trials used much lower amounts (0.5 mg combined with other vitamins) or extremely high amounts (50 mg by injection in one ALS trial). Those are study-specific, not general targets.

Vitamin B12 dosage depends on age, nutritional status, the reason for supplementation, the form of B12, the route of administration, and the cause of any deficiency. Recommended intakes, supplement doses and therapeutic doses answer different questions:

Term	What it means	Typical scale
Recommended dietary allowance (RDA)	Intake that meets the needs of nearly all healthy people	2.4 mcg/day (adults, US)
Supplement label dose	Amount manufacturers put in a product	Often 100 to 5,000 mcg per serving
Therapeutic dose	Amount used by clinicians or in trials to correct deficiency	Often 1,000 to 2,000 mcg oral daily, or 1,000 mcg IM per injection

Medical disclaimer: This article is educational. It summarizes published research and does not replace individualized medical advice, diagnosis or treatment. Doses used in studies are not prescriptions. If you suspect a B12 deficiency, have neurological symptoms, are pregnant, or take regular medication, speak with a qualified healthcare professional before changing your intake.

2. Why Vitamin B12 Dosage Depends on Form: Oral vs Injectable B12

Vitamin B12 (cobalamin) exists in several chemical forms, and it reaches the body by several routes. Both choices influence what dose is used in research and practice.

The four main forms

• Cyanocobalamin is the synthetic, highly stable form used in most supplements, fortified foods and many clinical trials. The body converts it to active forms.
• Methylcobalamin is one of the two active coenzyme forms. It is sold as a supplement and used in some trials, including a high-dose injection trial in ALS.
• Adenosylcobalamin is the other active coenzyme form, found in some supplements. Human dose-response data are limited.
• Hydroxocobalamin is the form commonly injected for deficiency in the United Kingdom and some other countries. It is retained in the body longer than cyanocobalamin after injection.

The routes

Oral tablets, capsules and liquids, sublingual tablets or lozenges, nasal and oral sprays, and intramuscular injections are all used. Oral absorption occurs by two mechanisms. The first is active: B12 binds intrinsic factor in the gut and is taken up in the ileum, a process that saturates at low amounts per meal. The second is passive diffusion, which absorbs roughly 1% of a dose regardless of intrinsic factor. This is why high oral doses (hundreds to thousands of mcg) can work even in people with impaired absorption, and why a dose of 2.4 mcg from a supplement is not equivalent to a 1,000 mcg tablet.

Injections bypass the gut. They are typically used when deficiency is severe, when neurological signs are present, or when absorption is considered unreliable. The Cochrane review of oral versus intramuscular therapy found that high-dose oral B12 produced similar blood B12 levels to injections in the trials analyzed, though the evidence was limited in size and quality (Wang et al., 2018).

Why a bigger label number is not automatically better

Because absorption of oral B12 falls steeply as the dose rises, a 5,000 mcg tablet does not deliver five times the usable B12 of a 1,000 mcg tablet. For people who simply need to meet dietary needs, much smaller amounts are sufficient. For people with deficiency, the cause (poor intake, loss of stomach acid, pernicious anemia, medications, surgery or disease of the ileum) decides whether oral therapy is reasonable or injections are preferred.

3. Human Study Dose Table

The table below summarizes selected human studies and one systematic review. They were chosen because they report B12 doses clearly and represent different purposes. Combination-vitamin trials are included only to show the scale of doses used and are marked as such, because their results cannot be attributed to B12 alone. Study details are summarized from published abstracts and should be checked against the full papers before being quoted.

Study (year)	Design and population	Objective	Form, dose, route, frequency	Duration	Main outcome	Key limitations
Eussen et al. (2005)	Randomized dose-finding trial; older adults (70+) with mild B12 deficiency	Find oral dose that corrects biomarkers	Oral cyanocobalamin, graded daily doses from a few mcg up to about 1,000 mcg	16 weeks	Estimated that roughly 650 to 1,000 mcg daily was needed for near-maximal lowering of methylmalonic acid	Biomarker endpoints; mild deficiency only; older adults
Wang et al. (2018, Cochrane)	Systematic review of 3 randomized trials; adults with B12 deficiency	Compare oral vs intramuscular treatment	Oral 1,000 to 2,000 mcg daily vs IM regimens (loading then maintenance)	Roughly 1 to 4 months	Similar serum B12 normalization with oral and IM routes	Few small trials; low certainty; few patients with severe neurological disease
Butler et al. (2006)	Pragmatic randomized trial in primary care; about 50 patients with low B12	Compare oral and IM therapy	Oral 1,000 mcg daily vs IM 1,000 mcg on a loading then spaced schedule	4 months	Oral therapy was not inferior for raising serum B12	Small; unblinded; blood level endpoint
Sharabi et al. (2003)	Randomized trial; about 50 patients with B12 deficiency	Compare sublingual and swallowed tablets	Oral vs sublingual cyanocobalamin, about 2,000 mcg daily	90 days	Both routes corrected B12 levels; sublingual route was at least equivalent	Small; short; no evidence of clear superiority
Kaji et al. (2019)	Phase 3 randomized, placebo-controlled; 130 patients with early ALS (Japan)	Test ultra-high-dose B12 as neurological therapy	Methylcobalamin 50 mg IM twice weekly	16 weeks	Slowed decline on a functional rating scale vs placebo	Not a deficiency study; early ALS only; single country; short
Lonn et al. (2006, HOPE-2)	Randomized trial; 5,522 adults with vascular disease or diabetes	Test homocysteine lowering for cardiovascular events	Combination: 1 mg B12 + 2.5 mg folic acid + 50 mg B6 orally, daily	About 5 years	Lowered homocysteine; no reduction in major cardiovascular events	Combination product; B12 effect cannot be isolated
Smith et al. (2010, VITACOG)	Randomized trial; 271 older adults with mild cognitive impairment	Test effect on brain atrophy	Combination: 0.5 mg B12 + 0.8 mg folic acid + 20 mg B6 orally, daily	24 months	Slower rate of brain atrophy, mainly in those with higher homocysteine	Combination; imaging surrogate endpoint
VITATOPS (2010)	Randomized trial; 8,164 adults after stroke or TIA	Test vitamins for preventing vascular events	Combination: 0.5 mg B12 + 2 mg folic acid + 25 mg B6 orally, daily	Median about 3.4 years	No significant reduction in the composite vascular outcome	Combination; participants not selected for deficiency

Two patterns stand out. First, trials built around correcting deficiency use roughly 1,000 to 2,000 mcg orally or 1,000 mcg intramuscularly. Second, large outcome trials in people who were not selected for deficiency used combination vitamins and generally did not show clinical benefit, which reinforces that supplementation helps most when a deficit exists.

4. Vitamin B12 Dosage by Health Outcome

For each condition below, it helps to separate three goals: prevention in people at risk, nutritional supplementation to meet dietary needs, and treatment of established deficiency. Doses differ greatly between them.

Confirmed deficiency

Treatment aims to replenish stores and normalize clinical and laboratory signs. Evidence from the trials above supports oral cyanocobalamin at about 1,000 to 2,000 mcg daily as comparable to injections for correcting blood levels in many patients (Wang et al., 2018; Butler et al., 2006). Injections remain common for severe cases, and the choice is a clinical one.

Megaloblastic anemia

Blood counts typically respond within days to weeks of adequate therapy. Treatment regimens in clinical guidelines generally start with a loading phase and then move to maintenance (see Section 6). Because folate deficiency produces a similar blood picture, the cause must be identified before treatment is assumed.

Neurological manifestations

Neurological involvement (numbness, balance problems, cognitive change) is where guidelines recommend more intensive and more closely supervised treatment. The British Society for Haematology guideline recommends intramuscular hydroxocobalamin with more frequent dosing for patients with neurological symptoms than for those without (Devalia et al., 2014). Delayed treatment can leave permanent damage, which is why this is not a self-treatment situation.

Dietary insufficiency and vegan or vegetarian diets

People who avoid animal foods depend on fortified foods or supplements. Prevention in this group uses the same low-to-moderate oral amounts that meet the RDA through fortified foods or supplements. Higher oral amounts used in deficiency trials are for people with a confirmed low status. Regimens vary: some guidance uses a small daily amount, others a larger weekly dose. Because absorption is dose-dependent, no single schedule is universal.

Older adults

Many older adults have reduced stomach acid, which impairs release of food-bound B12 but not absorption of crystalline B12 from supplements and fortified foods. The Eussen trial in this group is the most informative dose-finding study, with roughly 650 to 1,000 mcg daily estimated to correct biomarkers in mild deficiency. Intake recommendations for older adults specifically suggest meeting needs mainly through fortified foods or supplements.

Pregnancy and lactation

The RDA rises to 2.6 mcg in pregnancy and 2.8 mcg during lactation. Low maternal B12 status is linked to adverse outcomes in observational research, but high-quality dose-response trials in pregnancy are limited. Prenatal supplement amounts should be chosen with an obstetric care provider.

Malabsorption and pernicious anemia

Pernicious anemia is an autoimmune loss of intrinsic factor. Lifelong treatment is standard. Guidelines typically use intramuscular hydroxocobalamin with a maintenance interval of several months, and some patients are managed with high-dose oral therapy. People who have had ileal resection or gastric bypass, or who have Crohn's disease or celiac disease, may need the same approach. Trial evidence for oral therapy in severe malabsorption is more limited, so clinicians often choose injections initially.

Metformin and acid-suppressing medicines

Long-term metformin use is associated with a higher risk of low B12, and the risk appears to rise with duration (Aroda et al., 2016). Long-term use of proton pump inhibitors and histamine-2 receptor blockers was associated with higher odds of deficiency in a large observational study (Lam et al., 2013). These are associations, not dose-response trials. The practical point for readers is that monitoring B12 status is reasonable for long-term users, and any supplement amount is decided with a prescriber.

Other investigated outcomes

The homocysteine-lowering trials (HOPE-2, VITACOG, VITATOPS) tested B-vitamin combinations for cardiovascular and cognitive outcomes. HOPE-2 and VITATOPS did not reduce major vascular events. VITACOG found slower brain atrophy in a selected group. High-dose methylcobalamin has been studied in early ALS (Kaji et al., 2019). None of these results justifies B12 supplementation for these outcomes in people with adequate status.

5. Vitamin B12 Dosage by Formulation: Cyanocobalamin vs Methylcobalamin

Cyanocobalamin

Cyanocobalamin is the best-studied form for oral therapy and supplementation. Most deficiency dose-finding and oral-versus-injection trials used it. It is stable, inexpensive, and efficiently converted in the body.

Methylcobalamin

Marketing often presents methylcobalamin as the superior or more natural form. A review of the evidence concluded that coenzyme forms are not likely to be superior to cyanocobalamin or hydroxocobalamin for preventing or treating deficiency (Obeid et al., 2015). Methylcobalamin has been studied at very high doses in ALS, but that is a different question from treating dietary deficiency.

Hydroxocobalamin and adenosylcobalamin

Hydroxocobalamin is the standard injectable form in several countries and persists longer in the body after injection, which is why maintenance intervals may be longer than with cyanocobalamin. Adenosylcobalamin is available in some supplements, but human dose-response evidence is limited, so no study-based dose can be given.

Sublingual and spray products

In the Sharabi trial, sublingual and swallowed tablets at about 2,000 mcg daily both corrected deficiency. Because large oral amounts rely mostly on passive absorption, the mouth route does not appear to change the basic picture. The evidence does not show that sublingual products or sprays are superior to conventional oral tablets, and the available trials are small.

Oral vs injectable B12 in practice

The 2018 Cochrane review supports oral therapy as a reasonable option for many people. Injections are still preferred or required in several situations: severe neurological involvement, inability to take or absorb oral therapy, or when adherence to daily tablets is unlikely. This is a clinical decision.

6. Frequency of Administration

Study schedules fall into three patterns.

• Daily oral dosing. The most common approach in deficiency trials: 1,000 to 2,000 mcg once daily for several weeks to months, followed by a continuing daily or lower maintenance amount.
• Weekly or less frequent oral dosing. Some guidance for vegans and for maintenance uses a larger amount less often, relying on passive absorption to deliver a useful amount per dose. Evidence for specific weekly regimens is thinner than for daily ones.
• Injection schedules. Regimens usually include an intensive loading phase followed by maintenance. For example, the British guideline recommends hydroxocobalamin 1 mg intramuscularly three times a week for two weeks in deficiency without neurological involvement, then a maintenance interval of about every two to three months for pernicious anemia. For neurological involvement it recommends alternate-day injections until no further improvement, then every two months (Devalia et al., 2014). Other countries use different products and intervals.

A loading phase exists to refill depleted stores quickly. Maintenance exists because the underlying cause often persists. These schedules are clinical protocols; injection frequency should be set and monitored by a clinician rather than copied from a study.